Blinatumomab Active in Ph+ B-Precursor Acute Lymphoblastic Leukemia
Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor–relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.
Global Inequities in Childhood Leukemia Survival Still Persist
Global inequities in childhood leukemia survival have narrowed in recent years but still persist, according to data from CONCORD-2.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.
RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL
Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.
Pacritinib Induced Reduction in Splenomegaly, Myelofibrosis Symptoms
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.
Relapsed, Refractory Myeloma Has Indirect Societal Costs
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
By clicking Accept, you agree to become a member of the UBM Medica Community.